Nanoparticle Adjuvant Design Enhances Germinal Center Responses Targeting Conserved Subdominant Epitopes for Pan‐Coronavirus Vaccine Development
Advanced Science · 2026-02 · 13 (7)
DOI: 10.1002/advs.202512100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 25.11.2025. Verfasst von Sijin Huang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, 78712, USA. Hauptthemen laut MEDLINE: Germinal Center, COVID-19 Vaccines, SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, National Institute of Allergy and Infectious Disease.
Abstract (Originalsprache)
Current SARS‐CoV‐2 vaccines primarily elicit antibodies targeting the variable receptor‐binding domain in the S1 subunit of the spike protein, resulting in limited cross‐reactivity and short‐lived immunity against emerging variants. The conserved S2 subunit presents a promising vaccine target for broad and durable protection, but the immunodominance in vaccine‐induced germinal center (GC) responses hinders effective antibody generation against S2. Here, a polymeric toll‐like receptor 7 agonist nanoparticle (TLR7‐NP) adjuvant is reported, well designed to enhance lymph node targeting and more efficiently activate S2‐specific B cells. When combined with Alum‐adsorbed SARS‐CoV‐2 HexaPro spike protein, TLR7‐NP promotes early GC recruitment of S2‐specific B cells and overcomes the immunodominance, leading to early and robust S2‐specific antibody responses. Compared to conventional TLR7‐Alum adjuvanted subunit vaccine and clinically used SARS‐CoV‐2 mRNA vaccine, TLR7‐NP adjuvant induces stronger humoral immune responses across sarbecoviruses and betacoronaviruses and promotes long‐lived plasma cell and memory B cell formation. These findings present a direct B cell‐activating adjuvant approach for effective pan‐coronavirus vaccine development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, 78712, USA.
- Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, 78712, USA.
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, 10461, USA.
- Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
- Department of Chemical Engineering, Virginia Polytechnic Institute and State University, Blacksburg, VA, 24061, USA.
- LaMontagne Center for Infectious Diseases, The University of Texas at Austin, Austin, TX, 78712, USA.
ORCID-Profile: Qian Yin
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- National Institute of Allergy and Infectious Disease
- Cancer Prevention and Research Institute of Texas
- University of Texas at Austin Startup Fund, Texas Health Catalyst and the Cancer Prevention Research Institute of Texas
- Welch Foundation
- NHLBI NIH HHS
- National Cancer Institute
Zitieren
APA
Huang, S., Cohen, K. M., Chen, L., Kang, X., Liu, C., Demouth, M. E., Jiang, W., Maldeney, A. R., Tong, R., Ke, Z., Chandran, K., Luo, W., & Yin, Q. (2026). Nanoparticle Adjuvant Design Enhances Germinal Center Responses Targeting Conserved Subdominant Epitopes for Pan‐Coronavirus Vaccine Development. Advanced Science, 13(7). https://doi.org/10.1002/advs.202512100
Vancouver
Huang S, Cohen KM, Chen L, Kang X, Liu C, Demouth ME, et al. Nanoparticle Adjuvant Design Enhances Germinal Center Responses Targeting Conserved Subdominant Epitopes for Pan‐Coronavirus Vaccine Development. Advanced Science. 2026;13(7). doi:10.1002/advs.202512100
BibTeX
@article{Huang2026,
author = {Huang, Sijin and Cohen, Kanella M and Chen, Liqiang and Kang, Xiaowo and Liu, Chang and Demouth, Megan E and Jiang, Wenxia and Maldeney, Alexander R and Tong, Rong and Ke, Zunlong and Chandran, Kartik and Luo, Wei and Yin, Qian},
title = {Nanoparticle Adjuvant Design Enhances Germinal Center Responses Targeting Conserved Subdominant Epitopes for Pan‐Coronavirus Vaccine Development},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {7},
doi = {10.1002/advs.202512100}
}
EUVIMED